Quick Answer
Hepion Pharmaceuticals, Inc. reported Operating Income of -$4.16 million for fiscal year 2025.
Hepion Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$4.16M | +78.5% |
| 2024 | -$19.35M | +60.1% |
| 2023 | -$48.45M | -6.5% |
| 2022 | -$45.49M | -49.6% |
| 2021 | -$30.40M | -50.9% |
| 2020 | -$20.15M | -159.3% |
| 2019 | -$7.77M | +46.8% |
| 2018 | -$14.59M | +29.3% |
| 2017 | -$20.65M | +1.8% |
| 2017 | -$21.02M | -1.0% |
| 2016 | -$20.81M | -49.0% |
| 2015 | -$13.96M | -734.9% |
| 2014 | -$1.67M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$527.9K | +88.2% | +69.8% |
| June 30, 2025 | -$1.75M | +79.5% | -36.3% |
| March 31, 2025 | -$1.28M | +75.3% | +71.3% |
| September 30, 2024 | -$4.46M | +58.2% | +47.6% |
| June 30, 2024 | -$8.50M | +40.0% | -64.1% |
| March 31, 2024 | -$5.18M | +60.8% | +51.4% |
| September 30, 2023 | -$10.66M | -26.0% | +24.7% |
| June 30, 2023 | -$14.17M | +29.2% | -7.2% |
- Hepion Pharmaceuticals, Inc. showed an increase of +78.5% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, Hepion Pharmaceuticals, Inc.’s operating income has declined by 149.0% (from -$1.67 million to -$4.16 million).
- The most recent figure is from Hepion Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: